Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/LCTX/Capital expenditures

Lineage Cell Therapeutics, Inc. (LCTX) Capital expenditures 2016–2025

Lineage Cell Therapeutics, Inc. (LCTX) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.

$522,000FY2025 · since FY2016: $2.2M → $522,000
16171819202122232425
Fiscal yearValueYoY
FY2025$522,000-7.6%
FY2024$565,000-16.2%
FY2023$674,000+63.2%
FY2022$413,000+21.5%
FY2021$340,000+431.3%
FY2020$64,000-85.5%
FY2019$440,000-20.9%
FY2018$556,000-58.1%
FY2017$1.3M-41.0%
FY2016$2.2M—

Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.

Source: SEC XBRL filings · For reference only · Not investment advice

More LCTX financial trends

LCTX RevenueLCTX Net incomeLCTX Net marginLCTX Gross profitLCTX Gross marginLCTX Operating incomeLCTX Operating marginLCTX Operating cash flowLCTX Free cash flowLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →